Iridex reported that an international panel of glaucoma experts has published the second part of its best practices series for MicroPulse transscleral laser therapy (TLT), in Clinical Ophthalmology. Part 1 focused on patient dosimetry and patient selection, while part 2 addresses all other aspects of MicroPulse TLT treatment.

Ten glaucoma specialists with 3 or more years of MicroPulse TLT experience were recruited from Argentina, the Netherlands, Switzerland, and the United States to form an expert panel. A 3-round Delphi panel with the authors was held between December 2021 and February 2022. The first round polled the panel on treatment techniques, postprocedure management, expected outcomes, and retreatments/enhancements. The second round addressed specific treatment scenarios and defined treatment success and failure. The third round sought to clarify treatment techniques and rationales.

The panel concluded, “When used with proper energy settings, techniques, and treatment indications, MicroPulse TLT is a safe and effective treatment for many glaucomas and is a useful addition to the glaucoma treatment armamentarium.”